HOME > Investors >
Press Releases
2017-04-04
2016 Annual Report
2017-03-06
2016.06 (IR letter) Business Updates
2017-02-10
VM BioPharma Announces Publication of Phase 1/2 Clinical Data of Novel Gene Therapy VM202 in Amyotrophic Lateral Sclerosis (ALS)
2016-08-02
VM BioPharma Announces Korea Food and Drug Administration Approval of Phase 2 Clinical Trial for Investigational Gene Therapy VM202 in Ischemic Heart Disease
2016-09-08
ViroMed proceeding with the World’s first phase III gene therapy clinical trial for diabetic peripheral neuropathy (DPN)
1
2
3
4
5
6
7
8
9
10
